U.S. markets close in 5 hours 29 minutes
  • S&P 500

    4,282.89
    -14.25 (-0.33%)
     
  • Dow 30

    33,964.75
    +52.31 (+0.15%)
     
  • Nasdaq

    12,999.72
    -128.34 (-0.98%)
     
  • Russell 2000

    2,009.08
    -12.26 (-0.61%)
     
  • Crude Oil

    89.55
    +0.14 (+0.16%)
     
  • Gold

    1,792.00
    -6.10 (-0.34%)
     
  • Silver

    20.15
    -0.13 (-0.63%)
     
  • EUR/USD

    1.0191
    +0.0026 (+0.25%)
     
  • 10-Yr Bond

    2.8620
    +0.0710 (+2.54%)
     
  • GBP/USD

    1.2107
    +0.0048 (+0.40%)
     
  • USD/JPY

    134.2900
    +1.0180 (+0.76%)
     
  • BTC-USD

    23,863.53
    -265.79 (-1.10%)
     
  • CMC Crypto 200

    567.66
    -4.26 (-0.74%)
     
  • FTSE 100

    7,535.37
    +26.22 (+0.35%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FOSTER CITY, Calif., August 03, 2022--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005004/en/

Contacts

Aron Feingold
Investor and Media Relations
investor@geron.com
media@geron.com